• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Autolus Therapeutics plc (Amendment)

    2/14/23 5:02:32 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AUTL alert in real time by email
    SC 13G/A 1 tm236168d26_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Autolus Therapeutics plc

    (Name of Issuer)

     

    American Depository Shares, each representing one ordinary share, nominal value $0.000042 per share

    (Title of Class of Securities)

     

    05280R100

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: 

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO.  05280R100 Page 2 of 7

     

    CUSIP No.  05280R100
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power

    7,782,018

    (7) Sole dispositive power 0
    (8) Shared dispositive power

    7,782,018

    (9) Aggregate amount beneficially owned by each reporting person 7,782,018
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 4.7%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO.  05280R100 Page 3 of 7

     

    CUSIP No.  05280R100
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 7,782,018
    (7) Sole dispositive power 0
    (8) Shared dispositive power 7,782,018
    (9) Aggregate amount beneficially owned by each reporting person 7,782,018
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 4.7%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO.  05280R100 Page 4 of 7

      

    CUSIP No.  05280R100
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 7,782,018
    (7) Sole dispositive power 0
    (8) Shared dispositive power 7,782,018
    (9) Aggregate amount beneficially owned by each reporting person 7,782,018
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 4.7%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      Autolus Therapeutics plc (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
     

    The MediaWorks 191 Wood Lane London W12 7FP United Kingdom

       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    American Depository Shares, each representing one ordinary share, nominal value $0.000042 per share (the “Shares”).

     

     

     

    CUSIP NO.  05280R100 Page 5 of 7

      

    Item 2(e). CUSIP Number:
       
      05280R100 
       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: 
       
     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

       
    Item 4. Ownership:
       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2022, Nantahala may be deemed to be the beneficial owner of 7,782,018 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2022, each of the Reporting Persons may be deemed to be the beneficial owner of 4.7% of the total number of Shares outstanding.

     

     

     

    CUSIP NO.  05280R100 Page 6 of 7

      

    Item 4(c). Number of shares as to which such person has:

     

      Nantahala Capital Management, LLC 
       
      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 7,782,018
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 7,782,018
           
      Each of Messrs. Harkey and Mack
       
      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 7,782,018
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 7,782,018

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      The Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

      

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. 

     

     

     

    CUSIP NO.  05280R100 Page 7 of 7

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2023 NANTAHALA CAPITAL MANAGEMENT, LLC 
           
      By: /s/ Taki Vasilakis  
        Taki Vasilakis  
        Chief Compliance Officer  
           
      /s/ Wilmot B. Harkey  
      Wilmot B. Harkey   
           
      /s/ Daniel Mack  
      Daniel Mack  

     

     

     

    Get the next $AUTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUTL

    DatePrice TargetRatingAnalyst
    11/18/2024$7.00 → $7.60Neutral → Buy
    Goldman
    11/15/2024$13.00Neutral → Buy
    Redburn Atlantic
    11/9/2023$10.00Buy
    Deutsche Bank
    3/27/2023$8.00Overweight
    Wells Fargo
    3/17/2023$5.00Buy
    Bryan Garnier
    More analyst ratings

    $AUTL
    SEC Filings

    View All

    SEC Form 424B3 filed by Autolus Therapeutics plc

    424B3 - Autolus Therapeutics plc (0001730463) (Filer)

    1/26/26 4:09:22 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Autolus Therapeutics plc (0001730463) (Filer)

    1/26/26 4:07:48 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Autolus Therapeutics plc

    424B3 - Autolus Therapeutics plc (0001730463) (Filer)

    1/12/26 8:37:58 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Autolus Therapeutics upgraded by Goldman with a new price target

    Goldman upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $7.60 from $7.00 previously

    11/18/24 7:38:09 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics upgraded by Redburn Atlantic with a new price target

    Redburn Atlantic upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $13.00

    11/15/24 7:30:20 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Deutsche Bank initiated coverage on Autolus Therapeutics with a new price target

    Deutsche Bank initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $10.00

    11/9/23 6:38:44 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

    VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and toward precision biologics like mRNA and oncolytic viruses. The FDA is actively accelerating this cycle, having granted multiple breakthrough designations in January 2026 alone for platforms that demonstrate genuine survival durability[2]. This structural realignment positions Oncolytics Biotech Inc. (NASDAQ:ONCY), Moderna (NASDAQ:MRNA), Immunome (NASDAQ:IMNM), Autolus Therapeutics (NASDAQ:AUTL), and Prelude Therapeutics (NASDAQ:PRLD) within the emerging biological innovation c

    2/5/26 9:26:03 AM ET
    $AUTL
    $IMNM
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company's 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).

    2/4/26 8:57:41 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

    Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus anticipates full year 2026 AUCATZYL® net product revenue of $120 million to $135 millionIndependent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Focus for 2026 is: Driving AUCATZYL® top line growthOptimizing manufacturing operation to improve gross margin and innovating on next generation manufacturing platformProgressing the CATULUS, LUMINA and BOBCAT trials to expand the utility of obe-cel in pediatric hem-oncology and autoimmune

    1/12/26 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Leadership Updates

    Live Leadership Updates

    View All

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

    Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from

    4/16/25 1:00:00 AM ET
    $AUTL
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

    LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus' executive team and will lead the company's development organization effective September 30, 2024. "Matthias has a proven track record of success in pharmaceutical product development, achieving many key regulatory milestones and marketing approvals across several cancer indications," said Dr. Christian Itin, Chief Executive Officer of Autolus. "His in-depth development experience and leadership skil

    9/19/24 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 4:32:31 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 1:44:27 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 9:12:16 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Financials

    Live finance-specific insights

    View All

    Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

    Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data generation to support market growth and expansion continues; data in severe refractory systemic lupus erythematosus (srSLE) show no ICANS or high-grade CRS, demonstrate achievement of definition of remission in SLE (DORIS) in 83% (n=5/6) of patients and complete renal response (CRR) in 50% (n=3/6) of patientsLeadership team bolstered to support next phase of growth and optimization of business operationsConference call to be held today at 8:30 am EST / 1:30 pm GMT; conference call participants should p

    11/12/25 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

    LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its third quarter 2025 financial results and operational highlights before open of U.S. markets on Wednesday, November 12, 2025. Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are requi

    10/30/25 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

    Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and conditional European marketing authorization from the European Commission (EC) for AUCATZYL®Follow up data from the FELIX trial demonstrating obe-cel's potential for long-term remission in r/r B-ALL presented at the 2025 European Hematology Association (EHA) CongressCompany is on track to initiate Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) by year-end 2025Confere

    8/12/25 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care